Michael Maciocio allegedly misused confidential information about potential Pfizer deals to make trades himself and tip off a stockbroker friend.
If Anacor's treatment for eczema is approved by the FDA, Pfizer predicts peak-year sales could exceed $2 billion.
Be informed, get involved, and shape the world through finance. Read CFO.com's most recent headlines and standout stories.
The Obama Administration and the Allergan CEO disagree about whether the government wanted specifically to kill the giant drug merger.
A new study debunks the common notion that companies with high CSR ratings do not practice aggressive tax avoidance.
The presidential candidate would impose an "exit tax" on tax inversion deals that let U.S. firms reduce their taxes by merging with companies overseas.
Be informed, get involved, and shape the world through finance. Here's today's CFO roundup.
The companies predict the combined entity would have more than $25 billion in operating cash flow starting in 2018.
Blue chips, including P&G, Dupont, and Pfizer, feel the effects of "unprecedented currency devaluations."
When giant deals fail, life rarely goes back to normal.
In March the Treasury Department proposed an amendment to tax law, taking effect in 2015, that would prevent most corporate inversion transactions.
Amid a rush of spinoffs and carve-outs, parties to deals must watch out for people-related things they assume will work but won’t and important but often-overlooked considerations.
